Abstract
The role of cysteinyl leukotrienes (cysLTs; LTC4LTD4 and LTE4) in asthma has been well established (Drazen et al., 1999). However, cysLTs also contract isolated human pulmonary vascular preparations (Schellenberg and Foster, 1984; Bourdillat et al., 1987; Labat et al., 1992; Ortiz et al., 1995) and have been proposed to be involved also in vascular pathologies, for example pulmonary hypertension (Stenmark et al., 1983). This suggestion has received support from animal studies (Davidson and Drafta, 1992) but the precise function of cysLTs in the pulmonary circulation remains to be established. Previous studies have raised support for at least two different receptors for cysLTs (Labat et al., 1992; Coleman et al., 1995; Bäck et al., 1996; Dahlén, 1998). Human bronchi contain CysLTI receptors (Buckner et al., 1986) that are targets for the clinically used anti-asthmatic CysLTI antagonists (Drazen et al., 1999). The receptor present on the human pulmonary venous smooth muscle is however resistant to CysLTI antagonists and
is referred to asCysLT 2 (Labat et al., 1992). This communication will report on cysLT effects in human pulmonary arterial preparationsin vitro.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Back, M., Wikström Jonsson, E. and Dahlén, S.E., 1996, The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C, in the guinea-pig ileumEur J Pharmacol.317: 107.
Bourdillat, B., Haye-Legrand, I., Labat, C., Raffestin, B., Norel, X., Benveniste, J. and Brink, C., 1987, Effects of various pharmacological agents on isolated human bronchial and pulmonary arterial and venous muscle preparations contracted by LTDFundam Clin Pharmacol.1:433.
Buckner, C.K., Krell, R.D., Laravuso, R.B., Coursin, D.B., Bernstein, P.R. and Will, J.A., 1986, Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotrieneC4and leukotrieneD4. J Pharmacol Exp Ther.237:558.
Coleman, R.A., Eglen, R.M., Jones, R.L., Narumiya, S., Shimizu. T., Smith, W.L., Dahlén, S.E., Drazen, J.M., Gardiner, P.J., Jackson, W.T., Jones, T.R., Krell, R.D. and Nicosia, S., 1995, Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature.Adv Prostaglandin Thromboxane Leukot Res.23:283.
Dahlén, S.E., 1998, Leukotriene receptors: incompletely defined targets for treatment of asthma and inflammation, in:Five-lipoxygenase Products in AsthmaJ.M. Drazen, S.E. Dahlén, T.H. Lee, eds., Marcel Dekker, New York.
Davidson, D. and Drafta, D., 1992, Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4in the rat lungJAppl Physiol.73:955.
Drazen, J.M., Israel, E. and O’Byrne, P.M., 1999, Treatment of asthma with drugs modifying the leukotriene pathwayN Engl J Med.340:197.
Gaine, S.P. and Rubin, L.J., 1998, Primary pulmonary hypertensionLancet352:719.
Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J.Y., Leger, S., Masson, P., McFarlane, C.S., Piechuta, H., Rokach, J., Williams, H., Young, R.N., DeHaven, R.N. and Pong, S.S., 1989, Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotrieneD4receptor antagonist,Can J Physiol Pharmacol.67:17.
Krell, R.D., Aharony, D., Buckner, C.K., Keith, R.A., Kusner, E.J., Snyder, D.W., Bernstein, P.R., Matassa, V.G., Yee, Y.K., Brown, F.J., Hesp, B. & Giles, R.E., 1990, The preclinical pharmacology of ICI 204,219Am Rev Respir Dis.141:978.
Labat, C., Ortiz, J.L., Nord, X., Gorenne, I., Verley, J., Abram, T.S., Cuthbert, N.J., Tudhope, S.R., Norman, P., Gardiner, P. and Brink, C., 1992, A second cysteinyl leukotriene receptor in human lung.J Pharmacol Exp Ther.263:800.
Ortiz, J.L., Gorenne, I., Cortijo, J., Seller, A., Labat, C., Sarria, B., Abram, T.S., Gardiner, P.J., Morcillo, E. and Brink, C., 1995, Leukotriene receptors on human pulmonary vascular endothelium.Br J Pharmacol.115:1382.
Panettieri, R.A., Tan, E.M., Ciocca, V., Luttmann, M.A., Leonard, T.B. & Hay, D.W., 1998, Effects of LTD, on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonistsAm J Respir Cell Mol Biol.19:453.
Schellenberg, R.R. and Foster, A., 1984, Differential activity of leukotrienes upon human pulmonary vein and arteryProstaglandins27:475.
Stenmark, K.R., James, S.L., Voelkel, N.F., Toews, W.H., Reeves, J.T. and Murphy, R.C., 1983, LeukotrieneC4andD4in neonates with hypoxemia and pulmonary hypertension,N Engl J Med.309:77.
Walch, L., Labat, C., Gascard, J.P., de Montpreville, V., Brink, C. and Norel, X., 1999, Prostanoid receptors involved in the relaxation of human pulmonary vessels.Br J Pharmacol.126: 859.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bäck, M., Norel, X., Walch, L., Gascard, JP., Dahlén, SE., Brink, C. (2002). The Contraction of the Human Pulmonary Artery by LTC4 is Resistant to CYSLT1 Antagonists and Counteracted by Prostacyclin Release. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_48
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0193-0_48
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4960-0
Online ISBN: 978-1-4615-0193-0
eBook Packages: Springer Book Archive